Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL29129720 | 0.97 | GLRA1 (0.56) | GLRA1SLC6A9OR51E2ALDH1A1TSHR | |
| Glycine SCHEMBL3897442 | 0.92 | — | — | |
| Glycine SCHEMBL11469989 | 0.86 | — | — | |
| Piperazine SCHEMBL1415404 | 0.86 | GLRA1 (0.62) | GLRA1SLC6A9OR51E2ALDH1A1TSHR | |
| Pyrrolidine SCHEMBL28331515 | 0.84 | GLRA1 (0.42) | GLRA1SLC6A9OR51E2ALDH1A1 | |
| Cyclopentane SCHEMBL8428600 | 0.83 | GLRA1 (0.77) | GLRA1SLC6A9OR51E2ALDH1A1TSHR | |
| Cyclohexane SCHEMBL3895013 | 0.83 | GLRA1 (0.77) | GLRA1SLC6A9OR51E2ALDH1A1TSHR | |
| Glycine SCHEMBL8642558 | 0.83 | — | — | |
| Glycine SCHEMBL10595751 | 0.83 | — | — | |
| Piperidine SCHEMBL11192905 | 0.81 | ALDH1A1 (0.50) | OR51E2ALDH1A1TSHRSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843290-A | Therapeutic agent and therapeutic composition for amyotrophic lateral sclerosis | 学校法人庆应义塾 | 2019-06-04 | — | — | CN | disclosed |
| CN-109715185-A | Water soluble and chemically stable glucagon peptides | 印第安纳大学研究及科技有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-104447980-A | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers | UNIV INDIANA RES & TECH CORP | 2015-03-25 | — | — | CN | disclosed |
| CN-102088989-B | Glucagon analogs with enhanced solubility and stability in physiological pH buffers | UNIV INDIANA RES & TECH CORP | 2014-11-26 | — | — | CN | disclosed |
| EP-1942893-A4 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2011-10-12 | — | — | EP | disclosed |
| CN-102088989-A | Glucagon analogs with enhanced solubility and stability in physiological pH buffers | UNIV INDIANA RES & TECH CORP | 2011-06-08 | — | — | CN | disclosed |
| US-7947714-B2 | Piperidine glycine transporter inhibitors | Merck, Sharp & Dohme Corp. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1797035-A4 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1797035-A4 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1942893-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1942893-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007053400-A3 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1797035-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797035-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053400-A2 | PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006039221-A3 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |